Navigation Links
Savient Submits Biologics License Application (BLA) for pegloticase
Date:10/31/2008

EAST BRUNSWICK, N.J., Oct. 31 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced the submission of its BLA to the U.S. Food and Drug Administration (FDA) seeking approval to market pegloticase in the United States along with its request for a priority review. Savient's filing includes data from both the six-month placebo controlled Phase 3 pivotal trials, as well as data from the Open Label Extension (OLE) study. The data set includes 101 patients with at least twelve months continuous treatment.

"Filing the BLA for pegloticase is a major milestone for Savient," said Christopher Clement, President and Chief Executive Officer. "This filing reflects our commitment to changing the paradigm of therapy available to the treatment-failure gout population and brings us one step closer to commercializing this drug and offering a solution to patients who suffer from this debilitating disease."

The two replicate, six-month, Phase 3 clinical trials for pegloticase were performed under the auspices of a Special Protocol Assessment (SPA) and pegloticase was granted Orphan Drug designation by the FDA. The OLE study was established to allow patients who completed the Phase 3 program the opportunity to continue to receive pegloticase for an extended period of time.

ABOUT SAVIENT PHARMACEUTICALS, INC.

Savient Pharmaceuticals is a biopharmaceutical company engaged in developing and distributing pharmaceutical products that target unmet medical needs in both niche and broader markets. The company's product development candidate, pegloticase for treatment-failure gout, has reported positive Phase 1, 2 and 3 clinical data. Patient dosing in the Phase 3 clinical studies began in June 2006; patient
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Savient Pharmaceuticals to Hold Third Quarter 2008 Financial Results Conference Call on Thursday, November 6, 2008
2. Savients Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
3. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
6. AMDL Submits Data to FDA for Clearance to Market Its DR-70(R) Diagnostic Test to Monitor Colorectal Cancer Patients
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
9. Exelixis Submits XL139 Diligence Report to Bristol-Myers Squibb
10. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
11. MedImmune Submits Biologics License Application to FDA for Motavizumab

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...5 Biotech firm Replikins Ltd., whi...the 1918 pandemic through the prediction, outbreak... issued its latest biochemical analysis of the vir...1N1 ("Swine Flu") virus has dropped from its peak ...eak in the spring of 2009 to resting non-epidemic ...
(Date:11/25/2009)...,, BOCA RATON, Fla., Nov. 25 Fo...ot so for BodyLogicMD. The nation,s largest and f...lizing exclusively in medically supervised bioide...cians in its network since November 2008 - from...more physician-owned centers, including one in Pue...
(Date:11/25/2009)...Nov. 25 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. ...es, announced today that it executed,a joint ventu...ccine,Technology Co., Ltd. (Sinovac Dalian). The J...e human-use vaccines. Sinovac will contribute its ...ializing world-class vaccines; the,other party wil...
(Date:11/25/2009)... Ardea Biosciences, Inc. ...rt, Pharm.D., president and chief executive office...ealth Care Conference. , ,Presentation details ar...re Conference,Date: Tuesday, December 1, 2009...New York Palace Hotel, New York, NY,Webcast: <a...
Breaking Biology Technology:Biological H1N1 Vaccines: Too Little, Too Late 2Biological H1N1 Vaccines: Too Little, Too Late 3Biological H1N1 Vaccines: Too Little, Too Late 4Biological H1N1 Vaccines: Too Little, Too Late 5Nation's Largest Network of Doctors Specializing in Bioidentical Hormones Grows at an Exponential Rate 2Nation's Largest Network of Doctors Specializing in Bioidentical Hormones Grows at an Exponential Rate 3Nation's Largest Network of Doctors Specializing in Bioidentical Hormones Grows at an Exponential Rate 4Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 2Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 3Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference 2
... Oct. 10 Finesse Solutions, LLC,Santa Clara, CA, ...s for,life science process applications, announced...or control software. TruBio 3.4 software can autom...ons, ranging from 1L bench,top R&D glass to 1000L ...tware is optimized for DeltaV version 9.3 from Eme...
...INA, Oct. 10 /Xinhua-PRNewswire/ -- Beike,Biotechn...a global leader in,stem cell research and treatmen... it has signed eight separate mutual cooperation a...outstanding stem cell research organizations.,As p...a "Stem Cell Expert,Advisory Committee" and a sepa...
...teria Included a Focus on Research and Respect for...OLIS, Oct. 10 Eli Lilly and Company,(NYSE: LLY )...20,biopharmaceutical employers, according to the p...s 2008 survey polled nearly 4,000 employees from,5...al, pharmaceutical and,related industries. This ye...
Other Biology Technology:Finesse Solutions Launches TruBio 3.4 Bioreactor Control Software 2Stem Cell Leader Beike Signs 8 New Cooperation Agreements, Establishes Safety Monitoring Boards 2Stem Cell Leader Beike Signs 8 New Cooperation Agreements, Establishes Safety Monitoring Boards 3Lilly Recognized as One of the World's Top Biopharmaceutical Employers 2
(Date:11/25/2009)...ach, may be used to boost resistance to, or slow, ...l of Medicine researchers report in a study publis...nce . , Parkinson,s disease is caused by a degen...rain known as the substantia nigra, which is respo...n of dopamine in late-stage Parkinson,s causes sym...
(Date:11/25/2009)...t pumps some 250 million liters of blood through t...s of the heart have to be extremely durable. The r...ce chair of the Department of Medicine III at Heid... A. Katus), has discovered a protein that is respo...unit, the sarcomere. In cooperation with other res...
(Date:11/24/2009)...understanding how sounds associated with Navy sona...if they hear it at all. , The same type of large... detect flaws in the space shuttle,s behemoth soli...inside the giant head of a whale. The scans are pr...hale,s hearing anatomy using a breakthrough method...
Breaking Biology News(10 mins):Hormone ghrelin can boost resistance to Parkinson's disease 2New genetic cause of cardiac failure discovered 2Rocket science leads to new whale discovery 2Reportlinker Adds Pain Therapeutics 2005 3A Market Dynamics and Outlook 6124 1Reportlinker Adds Pain Therapeutics 2005 3A Market Dynamics and Outlook 6124 2Reportlinker Adds Pain Therapeutics 2005 3A Market Dynamics and Outlook 6124 3Reportlinker Adds Pain Therapeutics 2005 3A Market Dynamics and Outlook 6124 4Reportlinker Adds Pain Therapeutics 2005 3A Market Dynamics and Outlook 6124 5Reportlinker Adds Pain Therapeutics 2005 3A Market Dynamics and Outlook 6124 6Reportlinker Adds Pain Therapeutics 2005 3A Market Dynamics and Outlook 6124 7Reportlinker Adds Pain Therapeutics 2005 3A Market Dynamics and Outlook 6124 8Reportlinker Adds Pain Therapeutics 2005 3A Market Dynamics and Outlook 6124 9Reportlinker Adds Pain Therapeutics 2005 3A Market Dynamics and Outlook 6124 10Reportlinker Adds Pain Therapeutics 2005 3A Market Dynamics and Outlook 6124 11Reportlinker Adds Pain Therapeutics 2005 3A Market Dynamics and Outlook 6124 12Reportlinker Adds Pain Therapeutics 2005 3A Market Dynamics and Outlook 6124 13Reportlinker Adds Pain Therapeutics 2005 3A Market Dynamics and Outlook 6124 14Reportlinker Adds Pain Therapeutics 2005 3A Market Dynamics and Outlook 6124 15Reportlinker Adds Pain Therapeutics 2005 3A Market Dynamics and Outlook 6124 16Reportlinker Adds Pain Therapeutics 2005 3A Market Dynamics and Outlook 6124 17Reportlinker Adds Pain Therapeutics 2005 3A Market Dynamics and Outlook 6124 18Reportlinker Adds Pain Therapeutics 2005 3A Market Dynamics and Outlook 6124 19Reportlinker Adds Pain Therapeutics 2005 3A Market Dynamics and Outlook 6124 20Reportlinker Adds Pain Therapeutics 2005 3A Market Dynamics and Outlook 6124 21Reportlinker Adds Infections Ear Infections 6121 1Reportlinker Adds Infections Ear Infections 6121 2Reportlinker Adds Infections Ear Infections 6121 3Reportlinker Adds Infections Ear Infections 6121 4Reportlinker Adds Infections Ear Infections 6121 5Reportlinker Adds Infections Ear Infections 6121 6Anisakiasis hazard varies depending on the origin of the fish according to a study 61063 1Anisakiasis hazard varies depending on the origin of the fish according to a study 61063 2
...ctric lighting at night nearly a century ago has p..., ranging from improved safety and security to str... illumination can cause problems for stargazing, a... leading some people to say "lights out." , Balan...ghting has been a difficult undertaking, as too li...
...ntext of France,s presidency of the EU, Lille will...s. , The GMES (Global Monitoring for Environment ... services relating to the environment, climate cha...es. These services draw on data - mainly Earth obs...ements, combined with socio-economic data, process...
...rman . , Drought or deluge - scientists workin...nck Institute for Chemistry in Mainz, have now dis...w much of rainfall. Until now, the answers to thes...inconsistent. Andreae and his co-authors are now t...dictory effects that these tiny particles have on ...
Other Biology News:Lighting research center develops framework for assessing light pollution 2Lighting research center develops framework for assessing light pollution 3Major European program for the environment under the spotlight in Lille, France 2Moderate quantities of dirt make more rain 2Moderate quantities of dirt make more rain 3Moderate quantities of dirt make more rain 4Moderate quantities of dirt make more rain 5
... cells form from a hematopoietic stem cells called...o the bone surface and lowering the surrounding pH...l is then solubilized and the collagen degraded. O...ed primarily by Macrophage Colony-Stimulating Fact...
...c degradation is critical to the maintenance of ap...teins as important and diverse as those involved i...nse, antigen presentation, modulation of cell surf...ion, transcription, and signalling factors. The ub...
...in identification Service includes 1. Scanning of ...h-sensitive tryptic in-gel digestion and peptide e.... Acquisition of PMF (Peptide Mass Fingerprint) sp...cquisition of PFF (Peptide Fragmentation Fingerpri...
...ome Company has joined forces with the Mickle Labo...ome 411301 Tissue Chopper. This tissue sectioning ...ssue for metabolic experiments and to be especiall...lable at biopsy or from small organs. Its special ...
Biology Products: